Alligator Bioscience announced the appointment of Sumeet Ambarkhane, MD, as its Chief Medical Officer. In this role, Sumeet will provide medical leadership and direction in the development of Alligator's best-in-class preclinical and clinical pipeline, including Alligator's lead assets mitazalimab, a CD40 agonist currently in Phase II clinical development, and ATOR-1017, a 4-1BB agonist in Phase I. Sumeet is a seasoned professional with over 20 years of drug development experience in academia and in the biotechnology and pharmaceutical industries. Sumeet has a proven track record of advancing investigational medicines including immunotherapy-biologics, from early phases of development through regulatory approvals and adoption into clinical practice.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.913 SEK | +5.18% | +17.50% | +32.51% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+32.51% | 61.59M | |
+33.45% | 49.46B | |
+1.66% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+11.57% | 26.61B | |
-21.59% | 18.64B | |
+7.40% | 13.16B | |
+28.74% | 12.55B | |
+23.65% | 12.1B |
- Stock Market
- Equities
- ATORX Stock
- News Alligator Bioscience AB
- Alligator Bioscience Appoints Sumeet Ambarkhane as Chief Medical Officer